Last reviewed · How we verify

ARRY-438162, MEK inhibitor; oral

Array Biopharma, now a wholly owned subsidiary of Pfizer · Phase 2 active Small molecule

ARRY-438162, MEK inhibitor; oral is a MEK inhibitor Small molecule drug developed by Array Biopharma, now a wholly owned subsidiary of Pfizer. It is currently in Phase 2 development for Metastatic non-small cell lung cancer.

Inhibits MEK, a protein involved in the MAPK/ERK signaling pathway, which is often dysregulated in cancer.

Inhibits MEK, a protein involved in the MAPK/ERK signaling pathway, which is often dysregulated in cancer. Used for Metastatic non-small cell lung cancer.

At a glance

Generic nameARRY-438162, MEK inhibitor; oral
SponsorArray Biopharma, now a wholly owned subsidiary of Pfizer
Drug classMEK inhibitor
TargetMEK
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

ARRY-438162 works by blocking the activity of MEK, a key enzyme in the MAPK/ERK signaling pathway. This pathway is involved in cell division and growth, and is often overactive in cancer cells. By inhibiting MEK, ARRY-438162 can help slow or stop the growth of cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ARRY-438162, MEK inhibitor; oral

What is ARRY-438162, MEK inhibitor; oral?

ARRY-438162, MEK inhibitor; oral is a MEK inhibitor drug developed by Array Biopharma, now a wholly owned subsidiary of Pfizer, indicated for Metastatic non-small cell lung cancer.

How does ARRY-438162, MEK inhibitor; oral work?

Inhibits MEK, a protein involved in the MAPK/ERK signaling pathway, which is often dysregulated in cancer.

What is ARRY-438162, MEK inhibitor; oral used for?

ARRY-438162, MEK inhibitor; oral is indicated for Metastatic non-small cell lung cancer.

Who makes ARRY-438162, MEK inhibitor; oral?

ARRY-438162, MEK inhibitor; oral is developed by Array Biopharma, now a wholly owned subsidiary of Pfizer (see full Array Biopharma, now a wholly owned subsidiary of Pfizer pipeline at /company/array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer).

What drug class is ARRY-438162, MEK inhibitor; oral in?

ARRY-438162, MEK inhibitor; oral belongs to the MEK inhibitor class. See all MEK inhibitor drugs at /class/mek-inhibitor.

What development phase is ARRY-438162, MEK inhibitor; oral in?

ARRY-438162, MEK inhibitor; oral is in Phase 2.

What are the side effects of ARRY-438162, MEK inhibitor; oral?

Common side effects of ARRY-438162, MEK inhibitor; oral include Diarrhea, Nausea, Vomiting, Fatigue, Rash.

What does ARRY-438162, MEK inhibitor; oral target?

ARRY-438162, MEK inhibitor; oral targets MEK and is a MEK inhibitor.

Related